Fig. 3From: The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled studyMean change in facial blood flow from start of PACAP38/VIP infusion. PACAP38, pituitary adenylate cyclase-activating polypeptide 38; VIP, vasoactive intestinal peptideBack to article page